Narcolepsy
Alkermes Advances Narcolepsy Therapy with Promising Phase 2 Trial Results for Alixorexton
Alkermes; narcolepsy; alixorexton; Phase 2 trial; orexin 2 receptor agonist; narcolepsy type 1; normative wakefulness; late-stage testing; Vibrance-1 study; cataplexy; excessive daytime sleepiness
Takeda’s Oveporexton Succeeds in Two Phase III Trials, Paving Way for Narcolepsy Drug Filings
Takeda; Oveporexton; narcolepsy; Phase III trials; orexin agonist; FDA filing; Narcolepsy Type 1; clinical trial results
Axsome Therapeutics Narcolepsy Drug AXS-12 Achieves Phase III Success, Paving Way for US FDA Filing
Axsome Therapeutics, AXS-12, narcolepsy, Phase III trial, ENCORE trial, FDA filing, NDA
FDA Approves Avadel’s Lumryz for Pediatric Narcolepsy Patients
Avadel Pharmaceuticals, Lumryz, narcolepsy, pediatric patients, FDA approval, sodium oxybate, cataplexy, excessive daytime sleepiness (EDS)
Avadel Pharmaceuticals’ Narcolepsy Drug LUMRYZ Receives FDA Approval and Orphan Drug Exclusivity
Avadel Pharmaceuticals, LUMRYZ, narcolepsy, FDA approval, Orphan Drug Exclusivity, sodium oxybate, extended-release oral suspension
Centessa’s ORX750 Demonstrates Promising ‘Best-in-Class’ Profile in Early Narcolepsy Trial
Centessa Pharmaceuticals, ORX750, narcolepsy, orexin receptor 2 agonist, sleep-wake disorders, clinical trial, Phase 1 data
Takeda’s Orexin Narcolepsy Drug TAK-861 Poised for Phase III Trials After Promising Results
Takeda, TAK-861, narcolepsy, orexin receptor 2 agonist, Phase III trials, narcolepsy type 1, sleep disorders
Axsome Therapeutics’ Small Molecule AXS-12 Successful in Phase III Narcolepsy Trial
Axsome Therapeutics, AXS-12 (reboxetine), Phase III trial, Narcolepsy, Cataplexy reduction, Improved cognition/ memory/ sleepiness severity, Safety profile